Home
Live Updates
Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for ... : comparemela.com
Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for ...
NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell
Related Keywords
United States ,
Raleigh ,
North Carolina ,
Paris ,
France General ,
France ,
New York ,
American ,
Patricia Sosa Navarro ,
Pascalyne Wilson ,
Mark Frattini ,
Ashleyr Robinson ,
Arthur Stril ,
Nasdaq ,
European Medicines Agency ,
Cellectis The Company Euronext Growth ,
American Society Of Hematology ,
European Commission ,
Securities Exchange Commission ,
European Union ,
Committee For Orphan Medicinal Products ,
Euronext Growth ,
Orphan Drug Designation ,
Acute Lymphoblastic Leukemia ,
Chief Medical Officer ,
American Society ,
Dose Level ,
Orphan Medicinal ,
Nasdaq Global Market ,
Private Securities Litigation Reform Act ,
Annual Report ,
Sosa Navarro ,
Interim Chief Financial Officer ,
Lifesci Advisors ,
comparemela.com © 2020. All Rights Reserved.